Clinicopathologic and Prognostic Significance of Body Mass Index (BMI) among Breast Cancer Patients in Western China: A Retrospective Multicenter Cohort Based on Western China Clinical Cooperation Group (WCCCG)
Table 4
Risk of more aggressive clinicopathological features in patients with breast cancer according to menopausal status.
Characteristics
BMI at diagnosis for premenopausal patients (kg/m2)
BMI at diagnosis for postmenopausal patients (kg/m2)
<18.5
18.5-24.9
25-29.9
<18.5
18.5-24.9
≥25
OR (95% CI)
OR (95% CI)
OR (95% CI)
OR (95% CI)
OR (95% CI)
OR (95% CI)
Multifocality
1.14 (0.50, 2.27)
Reference
0.69 (0.41, 1.09)
0.21 (0.01, 0.97)
Reference
0.75 (0.45, 1.21)
ALN metastasis
0.95 (0.70, 1.28)
Reference
0.92 (0.79, 1.08)
0.70 (0.50, 0.97)
Reference
1.12 (0.96, 1.30)
Tumor size >5cm
0.87 (0.52, 1.41)
Reference
1.30 (1.05, 1.62)
1.16 (0.68, 1.90)
Reference
1.46 (1.16, 1.83)
Grade III
0.89 (0.56, 1.39)
Reference
1.11 (0.89, 1.38)
1.01 (0.61, 1.63)
Reference
1.24 (1.00, 1.54)
Lymphovascular invasion
0.59 (0.17, 1.47)
Reference
0.87 (0.55, 1.36)
0.30 (0.02, 1.43)
Reference
1.68 (1.04, 2.70)
HER2-positive
1.71 (1.02, 2.78)
Reference
0.85 (0.65, 1.12)
1.03 (0.57, 1.79)
Reference
1.01 (0.78, 1.32)
TNBC
0.79 (0.45, 1.32)
Reference
1.31 (1.03, 1.67)
1.30 (0.77, 2.11)
Reference
0.73 (0.57, 0.93)
P53 positive
0.66 (0.37, 1.19)
Reference
0.99 (0.73, 1.34)
0.82 (0.51, 1.34)
Reference
1.06 (0.83, 1.35)
Distant metastasis
2.59 (1.10, 5.36)
Reference
0.83 (0.44, 1.48)
0.53 (0.09, 1.74)
Reference
0.85 (0.52, 1.36)
Adjusted for age, tumor size, ALN, grade, ER, and HER2. ALN, axillary lymph node; HER2, human epidermal growth factor receptor-2; TNBC, triple negative breast cancer.
